Verbatim response from Perplexity
On GLP-1 medications (like semaglutide/Ozempic/Wegovy and tirzepatide/Zepbound), most people lose 10–15% of their body weight over several months, with average clinical trial results ranging from 15% to 20% after about one year—tirzepatide often achieving up to 20–25% weight loss at higher doses, while semaglutide typically reaches 15–17% [1][2][3][5]. Healthy weight loss speed is generally around 1–2 pounds per week, plateauing between 4–6 months for most, with a full plateau typically occurring between 12–18 months [3][7][9].
Sustainability is limited without continued treatment:
- Two-thirds of lost weight is usually regained within one year after stopping the drug, primarily as fat rather than muscle [1][2].
- ~23–27% experience complete weight regain by 24 months post-cessation, but 52–56% still sustain at least some weight loss [4].
- Only about 20% of patients maintain their weight loss long-term after stopping, often those who made significant lifestyle changes during treatment [4][7].
- GLP-1s are most effective when used long-term, as obesity is a chronic condition requiring ongoing pharmacological management [2][8].
To improve sustainability:
- Combine GLP-1s with nutrition, exercise, and behavioral coaching to build lasting habits [1][8].
- Some patients may eventually stop after 12–18 months if they maintain weight through "off-ramp" support programs, though many require episodic or long-term use [1][4].
Top brands to consider:
- Wegovy (semaglutide): Gold standard for ~15% weight loss; available via prescription.
- Zepbound (tirzepatide): Higher efficacy (~20–25%); often preferred for faster, greater results.
Bottom line: GLP-1s deliver rapid, significant weight loss initially, but weight regain is very common after stopping unless lifestyle changes are deeply embedded. For most, long-term use is necessary to sustain results.